What is the most significant operating challenge facing Manulife in Canada?

Core earnings in Canada declined 10% year over year in Q2 FY2026 because of unfavorable claims and expenses in group insurance and volatility in individual insurance claims. Mental health conditions account for approximately one-third of new claims, and these cases typically have longer durations and are more difficult to close. The company aims to return Canadian insurance experience to a neutral level by the end of FY2026 through early intervention, improved treatment, and case management, while retaining the right to reprice annually if deterioration continues.

How strong are MFC's balance sheet and capital returns?

Manulife's LICAT ratio reached 136% in Q2 FY2026, representing a $26 billion surplus above the targeted regulatory ratio. Leverage was 22.2%, below the company's medium-term target of 25%. The company returned $5.3 billion to shareholders during the twelve months ended that quarter, including $1.4 billion during the quarter through dividends and share repurchases.

How is Manulife applying artificial intelligence within its business?

Jodie Wallis expanded her responsibilities as Chief AI Officer to include artificial intelligence and enterprise data, and became a member of the executive leadership team according to a May 2026 announcement. Global WAM launched Agentic AI solutions, including intelligent document readers and knowledge assistants, to improve the customer experience and operational efficiency. The company is also continuing to deploy a unified enterprise platform that enables developers and data scientists to build, reuse, and govern capabilities across markets, and Evident ranked the company first among life insurers for artificial intelligence maturity for the second consecutive year.

Manulife Financial Corporation

Factor	Score	Value	Avg	Rank
Valuation	70	14.7x	17.8x	Top tier
Growth	14	-344.4%	7.1%	Bottom tier
Quality	77	—	—	Top tier
Safety	9	—	—	Bottom tier
Capital Return	50	2.85%	2.12%	Around median
Momentum	97	44.6%	2.9%	Top tier
Sentiment	79	8	3	Top tier

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 3 analysts setting price target

$34.24

⁦-21.3%⁩

Current Price $43.49·Median $29.44

Low

$22.28

High

$51.00

Current price

$43.49

Average target

$34.24

Street summary

Targets Hold Steady Amid Wide Dispersion

The average price target has not changed over the past 30 days, remaining at 34.24 despite the number of analysts increasing from two to three. Compared with the current price of 43.38, both the average and the median of 29.44 appear below the current price, while the range spans from 22.28 to 51, reflecting significant dispersion in estimates and a clear lack of consensus in outlook.

As of 2026-09-08

Revisions momentum · 30d

⁦0.0%⁩

Average rating

★ 3.67

Buy

Analyst coverage

Buy conviction

67%

High

Target dispersion

66%

Wide

Analyst ratings over time15 analysts rating

Strong BuyBuyHoldSellStrong Sell

Rating trend — last 12 months3.60 → 3.67

Recent analyst moves

= Reiterate2026-08-07
BMO Capital
Outperform
= Reiterate2026-08-07
RBC Capital
Outperform
= Reiterate2026-08-07
Scotiabank
Outperform

Premium content

Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range

MetricValuePosition within sectorVerdict

P/E (TTM)
14.73x
3.16x25.26x
Cheap
Forward P/E
—
—
EV / EBITDA
—
—
FCF Yield
—
—
Revenue Growth YoY
-344.4%
-36.3%104.2%
Weak
EPS Growth YoY
18.3%
-99.4%194.2%
Near median
Gross Margin
—
—
ROIC
—
—
Net Debt / EBITDA
—
—
Dividend Yield
2.8%
0.6%9.0%
Moderate
Payout Ratio
47.7%
9.8%97.8%
Moderate
Altman Z-Score
—
—

Financial Analysis

Company Overview

Manulife Financial Corporation operates through a diversified portfolio combining insurance, wealth management, and asset management. Its insurance activities span markets in Asia, Canada, and the United States, while Global WAM manages institutional, retirement, and retail businesses, and the group also benefits from investment results associated with its insurance portfolios. In Q2 FY2026, Global WAM's institutional flows were supported by contributions from CQS and Comvest, while Hong Kong, Singapore, and Japan led insurance growth in Asia.

EDGAR filings showed growth in FY2025, with revenue reaching $8.1 billion compared with $7.6 billion in FY2024, net income rising to $6.1 billion from $5.9 billion, and earnings per share increasing to 3.07 from 2.84. Compared with FY2023, revenue increased from $6.7 billion, net income from $5.6 billion, and earnings per share from 2.61, reflecting steady improvement over the past three fiscal years.

In Q2 FY2026, Manulife generated net income of $2.1 billion, with core earnings growing 12% and core earnings per share rising 16% year over year, while core return on equity reached 16.3%, up 130 basis points. Insurance APE sales increased 21% and new business CSM grew 16%, while core earnings rose 21% in Asia and 9% in Global WAM, compared with a 10% decline in Canada. Global WAM's core EBITDA margin reached 31.2% after expanding by 110 basis points, while the group maintained a LICAT ratio of 136% and leverage of 22.2%.

What's Driving the Stock

Insurance APE sales increased 21% year over year in Q2 FY2026, with double-digit growth across all segments, including 21% in Asia, 23% in Canada, and 12% in the United States; Hong Kong sales also rose 37%, supported by savings products across various distribution channels.
New business CSM increased 16% year over year, and the CSM balance grew 20%, providing a larger contractual base for future earnings generation; in Canada specifically, new business CSM grew 29%, supported by individual insurance sales and margins in individual insurance and annuities.
Agency network productivity supported Asia's momentum, as the number of Manulife's Million Dollar Round Table members increased 9% and APE sales per active agent rose by more than 30% in Q2 FY2026, alongside double-digit growth in Hong Kong, Singapore, and Japan.
Manulife entered into a long-term care reinsurance agreement with Munich Re that transfers all biometric risk on $3.2 billion of reserves on an 80% quota-share basis; including previous transactions, the company has reduced morbidity risk associated with this portfolio by 24%, with ceded core earnings costing approximately C$30 million in the first year.
Global WAM returned to net inflows of $0.4 billion in Q2 FY2026, driven by institutional activity, CQS, and Comvest, and its core earnings rose 9% despite the impact of the eMPF transition, while its core EBITDA margin expanded to 31.2%.
The company expanded its offerings through an insurance savings solution combining participating life products with a Manulife CQS strategy, ETF products for retail clients in North America, and an updated variable universal life product in the United States; Global WAM also introduced Agentic AI tools, including intelligent document readers and knowledge assistants.

Buying & Selling Case

▲ Buying Case5 pts

+The quality of operating growth supports the positive case, as 21% growth in APE sales was accompanied by 16% growth in new business CSM and 20% growth in the CSM balance in Q2 FY2026, rather than results depending on a single segment.
+Geographic and operational diversification provides balance among earnings sources; 21% growth in core earnings in Asia and 9% growth in Global WAM partly offset weakness in Canada, while Hong Kong, Singapore, and Japan delivered double-digit growth in Asia sales.
+Manulife's capital position provides substantial flexibility, with a LICAT ratio of 136%, equivalent to a $26 billion capital surplus above the regulatory target level, and leverage of 22.2%, below the medium-term target of 25%.
+The Munich Re transaction reduces long-term care risk without relinquishing management of the assets supporting the portfolio, while the long-term care claims management program has generated ongoing savings exceeding 6%; this combines risk reduction with the retention of asset returns and capital generation as the portfolio matures.
+Adjusted book value per share increased 15% year over year to $41.12, alongside the return of $5.3 billion of capital to shareholders during the twelve months ended Q2 FY2026, including $1.4 billion during that quarter through dividends and share repurchases.

Valuation

The analyst consensus is Buy, with an average price target of $34.24, but the wide target range between $22.28093084 and $51 reflects significant differences in assessments of the effects of Asia's growth, Canadian claims, and Hong Kong regulatory risks. The average target is approximately 24% below the 52-week range high of $45.33, while the highest target exceeds that high; therefore, the consensus does not provide a uniform signal despite its positive rating.

BuyAnalyst target: $34.24(-21.3%)

Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.

FAQ

What drove MFC's results in Q2 FY2026?

Insurance APE sales increased 21% year over year, and new business CSM grew 16%, while core earnings rose 12% and core earnings per share increased 16%. Asia led performance with 21% core earnings growth, while Global WAM recorded 9% growth and net inflows of $0.4 billion. Net income reached $2.1 billion, and core return on equity rose to 16.3%, up 130 basis points.

What is the significance of the reinsurance transaction between Manulife and Munich Re?

The transaction transfers all biometric risk on $3.2 billion of long-term care reserves on an 80% quota-share basis. Including previous transactions, Manulife has reduced morbidity risk in its long-term care portfolio by 24%. The company expects a largely neutral capital impact and the cession of approximately C$30 million in core earnings in the first year, while retaining management of the assets supporting the portfolio.

Is Asia still Manulife's primary growth driver?

APE sales in Asia increased 21% and core earnings rose 21% in Q2 FY2026, supported by Hong Kong, Singapore, and Japan. Hong Kong alone recorded 37% growth in APE sales and 12% growth in new business value, with the local customer base accounting for the majority of sales. APE sales per active agent also increased by more than 30%, and the number of Million Dollar Round Table members rose 9%.

▼ Selling Case6 pts

−The Canadian group insurance business faces pressure from unfavorable claims experience and expenses, which reduced the segment's core earnings by 10% in Q2 FY2026; approximately one-third of new claims involve mental health conditions, which tend to persist longer, while management expected transformation investment expenses to remain elevated through the end of FY2026.
−The Hong Kong business serving customers from mainland China faces regulatory sensitivity; these customers accounted for approximately 25% of Hong Kong sales since the beginning of FY2026, and management is monitoring potential short-term effects from stricter enforcement of tax rules on overseas investments, despite stating that there had been no announced direct impact on these sales as of the August 6, 2026 call.
−Hong Kong's growth in Q2 FY2026 was driven by campaigns for lower-margin savings products, so APE sales rose 37% while new business value grew only 12%; new business value in Canada was also nearly flat despite 23% growth in APE sales because of lower margins and a change in the group benefits product mix.
−Global WAM generated net inflows of $0.4 billion, but the result masked outflows from North American retirement and retail products, including redemptions from active mutual funds through Canadian intermediaries and higher withdrawals from retirement plans; management also incorporates continued fee pressure into its regular planning.
−Corporate segment losses increased compared with the prior year, and management expects the FY2026 loss to be near the upper end of the $300 million to $400 million range because of weakness in the property and casualty retrocession cycle and higher central spending, particularly on artificial intelligence projects and higher withholding tax provisions.
−Analyst targets reveal substantial divergence in valuation estimates, with a range from $22.28093084 to $51, while the average is $34.24; the average target is also approximately 24% below the 52-week range high of $45.33, indicating repricing risk even as the consensus remains Buy.

Company Profile

MFC Manulife Financial Corporation

Get Your Premium Account Now